Home use vs clinical use

"Home use" and "clinical use" are usually presented as a preference — where you would rather have the chamber. On the current record they are closer to two different regulatory positions, with different purchase conditions, different supervision expectations, different building requirements, and a materially different safety history. It is worth knowing which one you are stepping into before you look at a price.

Nobody publishes an FDA document authorising home use

We looked for one. The two cleared low-pressure chamber families we can read in full specify a clinical or physician-directed setting: the Summit to Sea fabric chambers are cleared "as prescribed by or under the direction of a physician" (K072757), and the Revitalair 430+ is cleared under prescription and "designed for use at physician offices and health institutions" (K220290). Claims that 510(k) clearance authorises use "in clinical settings as well as private residences" appear on seller pages, but we could not corroborate them against any FDA document.

That is not the same as saying home ownership is prohibited. It is saying something narrower and more useful: if a seller tells you a specific chamber is cleared for home use, ask which K-number says so, and read that clearance's Indications for Use. Some clearances may say more than the two above. The generalisation across the category is what we could not substantiate.

Prescription status applies either way. FDA's own words: "Hyperbaric oxygen chambers are prescription devices" (FDA CDRH letter, 22 August 2013), and 21 CFR 801.109 conditions the prescription exemption on the device being sold "only to or on the prescription or other order of such practitioner" (GPO text). A cart checkout with no practitioner order does not obviously satisfy that condition. Buyers should expect a prescription step from any seller taking that seriously — including from us.

The professional societies are not neutral on this

UHMS states: "The UHMS does not endorse the concept of 'In Home' therapy at any time," and recommends "that physicians or, as permitted by local regulations, supervised non-physician providers who are appropriately trained in Undersea and Hyperbaric Medicine, be available immediately throughout the administration of hyperbaric oxygen therapy" (UHMS Position Statement, revised 10 July 2018).

We sell equipment to people who intend to use it at home, so we have an obvious incentive to skip that quotation. It stays because a buyer who does not know the professional position cannot make an informed decision about supervision, and supervision is the variable that shows up in the incident record.

The 2025 safety letter changed what a careful buyer should assume

In August 2025 FDA wrote: "The FDA is aware of reports of serious injuries and deaths with use of HBOT devices," and "The FDA is aware of recent reports of fires that occurred with HBOT devices that resulted in serious injuries and deaths. Currently, the root cause of these events is not known. While the FDA believes that serious adverse events associated with HBOT devices are rare, health care providers and users should be aware that these events can and do occur." Its recommendations include ensuring fire prevention and safety measures are followed, awareness of "a heightened risk of fire with use of oxygen at a high concentration," proper grounding, maintained staff training, controls on prohibited items "including electrical or static devices," clothing "made of hyperbaric compatible materials … such as cotton," and ensuring "the patient is properly monitored and supervised for the duration of the treatment" (FDA Letter to Health Care Providers, 25 August 2025).

Read the last item against the adverse-event record. Twelve death reports are indexed under product code CBF in FDA's MAUDE database. The two most recent, both with event date 9 July 2025, involve the same chamber model: one describes a person "found deceased inside of a hyperbaric oxygen chamber at his health clinic," with responders determining "that a flash fire occurred while [he] had been undergoing self-treatment inside the sealed chamber"; the other describes "a male clinic founder [who] died in a flash fire inside an OxyHealth Fortius 420 hyperbaric chamber during self-treatment," and notes he had recently completed a safety and certification course (openFDA MAUDE death reports for product code CBF).

Two features of those reports matter for a home buyer. Both were self-treatment. And in one case the occupant had completed formal training. Training is worth having and is not a substitute for someone outside the chamber who can act.

What "clinical use" imposes that home use does not

If the chamber goes into a commercial or healthcare setting, a body of building requirements comes with it. NFPA 99 Chapter 14 classifies chambers by occupancy: "Class A – Human, multiple occupancy; Class B – Human, single occupancy; Class C – Animal, no human occupancy." For a Class A chamber inside a building, "the chamber(s) and all ancillary service equipment shall be protected by 2-hour fire-resistant-rated construction," while Class B and C chambers inside a building are not required to have that rating. Where a Class A or Class B chamber is housed, "the room or rooms … shall be for the exclusive use of the hyperbaric operation," and a sprinkler system to NFPA 13 or a water mist system to NFPA 750 "shall be installed in the room housing a Class A, Class B, or Class C chamber and in any ancillary equipment rooms" (NFPA 99, 2015 edition, Chapter 14, clauses 14.1.2.2, 14.2.1.1, 14.2.1.1.2, 14.2.1.1.7 and 14.2.1.2).

Two notes on that. First, the edition matters — a jurisdiction adopts a specific edition of NFPA 99, and yours may not be the 2015 edition quoted here, so the applicable text is whichever your authority having jurisdiction enforces. Second, "exclusive use of the hyperbaric operation" is the clause most often discovered late. UHMS puts the same point in plainer language: "The room housing your hyperbaric chambers is designed to provide medical treatment – therefore, it is a medical treatment room and not a storage closet" (UHMS standards and codes FAQ).

FDA's own consumer advice pointed at accredited facilities: if a provider recommends hyperbaric oxygen therapy, "the FDA advises you get the treatment at a hospital or facility that has been inspected and is accredited by the Undersea and Hyperbaric Medical Society," and it noted that "Explosions and fires have occurred in HBOT chambers that have not been reviewed by the FDA and are located at unaccredited facilities" (FDA bulletin, 26 July 2021; archived consumer update).

A blunt comparison

Choosing honestly

The home path is legitimate for a low-pressure air environment where a prescription has been obtained, a second competent person is present, and the buyer has read the fire guidance rather than assumed lower pressure removes the risk. It is a poor path if the plan involves an oxygen concentrator feeding a chamber not cleared for one, or unattended sessions, or an expectation of reproducing clinical exposures.

The clinical path is the right one if the chamber has to earn, if higher pressures are the point, or if the buyer wants the accountability structure that accreditation and code compliance provide. It costs more before the chamber arrives than most first-time buyers budget, and almost all of that extra cost is in the room rather than the equipment. The costs nobody quotes puts numbers and sources against that.